DIRA Data Integrity Risk Assessment: Introductory Guide

Data Integrity is now one of the pillars of pharmaceutical compliance: more than 60% of recent FDA Warning Letters relate to data integrity deficiencies, often caused by insufficient controls or non-structured processes.

The DIRA – Data Integrity Risk Assessment was created precisely to prevent such risks. It is the application of Quality Risk Management (ICH Q9) to the data lifecycle and represents the most effective methodology for identifying vulnerabilities in processes, systems and operational practices.

---

👉 What a DIRA Is and Why It Matters

According to WHO and PIC/S guidelines, companies must perform a Data Integrity Risk Assessment to identify and evaluate risks across the entire data lifecycle: data generation, recording, processing, use, storage and retrieval.

A DIRA allows companies to:

• identify risks related to ALCOA+ attributes (Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available)
• assess data criticality and the likelihood of errors or manipulation
• apply controls proportionate to data risk
• integrate Data Integrity into the PQS and into corporate Data Governance

Regulatory authorities now consider DIRA a mandatory best practice in modern quality systems: the WHO clearly states that it should be applied to all processes and systems generating GxP data.

---

DIRA and Regulations: What Inspectors Expect

Inspectors expect companies to be able to:

• map data flows across critical processes
• identify risks at each stage of the data lifecycle
• implement controls consistent with the risk level of the data
• clearly document analysis, actions and follow-up

The absence of a DIRA is considered evidence of a weak PQS and insufficient Data Governance.

---

Practical Benefits of a DIRA

• Reduction of deviations and Warning Letters
• Stronger control over computerized and manual processes
• More robust decision-making (QA/QP)
• Increased inspection readiness for EMA/FDA audits
• Structured baseline for continuous improvement

---

Real Inspection Examples

The guide highlights common non-compliance patterns:

• Shared accounts in laboratories (violation of Attributable)
• Audit trail not enabled or not reviewed (violation of Original/Accurate)
• Late or backdated entries (violation of Contemporaneous)
• Untested backups (violation of Enduring/Available)

All of these risks can be identified and mitigated through a well-executed DIRA.

---

🎯 Career Impact

Being able to conduct or evaluate a DIRA significantly increases the competitiveness of QA, QC, RA, Validation and Manufacturing professionals. Companies seek individuals capable of mapping risks, proposing controls and supporting demanding audits.

---

❓ FAQ

1. Who should conduct a DIRA?
A multidisciplinary team: QA, IT, QC, Production, CSV, Data Owner.

2. How often should it be updated?
At least annually or following significant changes (new systems, deviations, audits).

3. Is a DIRA mandatory?
It is required by WHO and recommended by FDA, EMA and PIC/S.

4. Does DIRA apply only to digital systems?
No — paper-based and hybrid processes also carry significant risks.

---

Conclusion

The DIRA is a strategic tool: it protects product quality, strengthens compliance and prevents future inspection findings. Discover the complete guide at GuideGxP.com